XAIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Beyond Air Inc (XAIR) is not a strong buy at this time for a beginner investor with a long-term strategy. Despite the pre-market price increase of 5.57%, the technical indicators show a bearish trend with oversold conditions, and there are no significant positive catalysts or trading signals to support immediate action. The company's financial performance shows revenue growth, but profitability metrics are declining significantly. Analysts have lowered price targets, and there are no recent influential trades or news to indicate a strong upside.
The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. The MACD histogram is negative and expanding, indicating downward momentum. RSI_6 is at 15.006, signaling oversold conditions. Key support levels are at 0.488 and 0.396, while resistance levels are at 0.638 and 0.787.
Revenue increased by 104.66% YoY in Q3 2026, indicating potential growth in sales. Analysts see potential in the commercialization of the LungFit PH system, though this is a long-term catalyst.
No recent news or significant trading trends from insiders, hedge funds, or Congress.
In Q3 2026, revenue increased to $2,194,000 (up 104.66% YoY), but net income dropped to -$7,336,000 (down 43.71% YoY). EPS declined to -0.85 (down 71.28% YoY), and gross margin fell to 13.67 (down 168.15% YoY).
Analysts have a Buy rating but have lowered price targets. JonesResearch reduced the target from $6 to $2, citing delays in FDA approval and revised sales estimates. Rodman & Renshaw initiated coverage with a $5 price target, but this is contingent on long-term catalysts.
